3 assets in Bladder Clear Cell Adenocarcinoma

Therapeutic assets addressing Bladder Clear Cell Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Bladder Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Bladder Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Bladder Clear Cell Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)